期刊文献+

比伐卢定联合替罗非班治疗急性心肌梗死临床疗效及对心脏不良事件的影响 被引量:2

下载PDF
导出
摘要 目的:探究比伐卢定联合替罗非班治疗急性心肌梗死临床疗效及对心脏不良事件的影响。方法:对两组分别给予比伐卢定治疗和比伐卢定联合替罗非班治疗。结果:研究组术后ST段回降率>70%的占93.94%,要比对照组的83.33%更高(P<0.05);研究组术后冠脉血管血流TIMI分级为3级的比例为90.91%,要比对照组TIMI3级的更高(P<0.05);术后一个月研究组再发心绞痛、心力衰竭、出血心脏不良事件发生率为7.58%,比对照组更低(P<0.05)。结论:比伐卢定联合替罗非班治疗急性心肌梗死具有较好的效果,可以有效促进ST段回降,改善心肌灌注,并减少术后不良心脏事件的发生。
出处 《北方药学》 2019年第11期42-43,共2页 Journal of North Pharmacy
  • 相关文献

参考文献9

二级参考文献54

  • 1张辉锋,董平栓,王可,杨旭明,王绍欣,李志娟,王红雷,邢适颖.药物干预冠状动脉介入治疗术中无复流、慢血流的疗效分析[J].中国医学前沿杂志(电子版),2012,4(10):63-66. 被引量:6
  • 2KUSHNER FG, HAND M, SMITH SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST- elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American Callege of Cardialogy Foundation/American HeartAssociation Task Force on Practice Guidelines[J]. J Am Coil Cardial, 2009, 54(23): 2205-2241.
  • 3RESNIC FS, WAINSTCIN M, LEE MK, et aL No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention[J]. Am Heart J, 2003, 145 (2): 42-46.
  • 4THIDE H, SEHINDLER K, FRIEDENBERGER J, et al. Intracoronary compared with intravenous balus abciximab application in patients with ST- elevation myocardial infarction undergoing primary percutaneous coronary intervention :the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial[J]. Circulation, 2008, 118( 1 ): 49-57.
  • 5WANG HL, XING SY, DONG PS, et al. Safety and efficacy of intracoronary tirofiban administration in patients with serious thrombus burden and ST-elevation myocardial infarction under- going percutaneous coronary intervention[J]. Eur Rev Med Pharmacal Sei, 2014, 18(23): 3690-3695.
  • 6MEHRAN R, LANSKY AJ, WITZENBICHLER B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS- AMI): 1- year results of a randomised contralled trial[J]. Lancet, 2009, 374(9696): 1149- 1159.
  • 7CAIXETA A, LANSKY AJ, MEHRAN R, et al. Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS- AMI trial[J]. Eurointervention, 2013, 9(2): 220-227.
  • 8GIBSON CM, MURPHY SA, RIZZO M J, et al. Relationship between TIMI frame count and clinical outcomes after thrombalytic administration. Thrombalysis In Myoardial Infarction (TIMI) Study Group[J]. Circulation, 1999, 99(15): 1945-1950.
  • 9BLANKENSHIP JC. Bleeding complications of gIycoprotein I1 b/ I a receptor inhibitors[J]. Am Heart J, 1999, 138 (4 Pt2): $287-$296.
  • 10VALGIMIGLI M, CAMPO G, MALAGUTTI P, et aL Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a poaled analysis from the STRATEGY (Single High- Dose Balus Tirofiban and Siralimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Muhicenter Evaluation of Single High- Dose Balus Tirofiban Versus Abciximab With Siralimus- Eluting Stent or Bare- Metal Stent in Acute Myocardial Infarction Study) trials[J]. JACC Cardiovasc Interv, 201 l, 4( 1 ): 51-62.

共引文献96

同被引文献19

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部